To evaluate which of these shortlisted miRs displayed higher tissue expression in HER2-positive patient tumour samples than in HER2-negative patient tumour samples (suggesting a relevance to the HER2 signalling pathway), we performed NanoString nCounter® miR analysis in NCI-N87, FLO-1, and MAGIC trial (ISRCTN93793971) formalin-fixed paraffin-embedded (FFPE) oesophago-gastric cancer patient samples. This evidence concerns the gene ERBB2 and neoplasm.